Abstract

RNA-protein interactions (RPIs) are promising targets for developing new molecules of therapeutic interest. Nevertheless, challenges arise from the lack of methods and feedback between computational and experimental techniques during the drug discovery process. Here, we tackle these challenges by developing a drug screening approach that integrates chemical, structural and cellular data from both advanced computational techniques and a method to score RPIs in cells for the development of small RPI inhibitors; and we demonstrate its robustness by targeting Y-box binding protein 1 (YB-1), a messenger RNA-binding protein involved in cancer progression and resistance to chemotherapy. This approach led to the identification of 22 hits validated by molecular dynamics (MD) simulations and nuclear magnetic resonance (NMR) spectroscopy of which 11 were found to significantly interfere with the binding of messenger RNA (mRNA) to YB-1 in cells. One of our leads is an FDA-approved poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor. This work shows the potential of our integrative approach and paves the way for the rational development of RPI inhibitors.

Data availability

All data are available within the Article, Supplementary Files and Appendices, or available from the corresponding authors on reasonable request. Source data for figures 2, 4d, 7b, Figure 3-Figure supplement 3, Figure 8a, Figure 8-Figure supplement 1b-c, Figure 8-Figure supplement 4b-c, Appendix 5 Table 1 and Appendix 5 Figure 1 are also provided with the paper.

Article and author information

Author details

  1. Krystel El Hage

    Department of Chemistry, Université Paris-Saclay, INSERM U1204, Evry, France
    For correspondence
    krystel.elhage@unibas.ch
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4837-3888
  2. Nicolas Babault

    SYNSIGHT, Evry, France
    Competing interests
    Nicolas Babault, Synsight has acquired a license for the MT bench" patent (WO2016012451A1) concerning the industrial applications. Nicolas Babault is affiliated with SYNSIGHT. The author has no financial interests to declare.".
  3. Olek Maciejak

    Department of Chemistry, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9594-9435
  4. Bénédicte Desforges

    Department of Chemistry, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  5. Pierrick Craveur

    SYNSIGHT, Evry, France
    Competing interests
    Pierrick Craveur, Synsight has acquired a license for the MT bench" patent (WO2016012451A1) concerning the industrial applications. Pierrick Craveur is affiliated with SYNSIGHT. The author has no financial interests to declare.".
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9274-4944
  6. Emilie Steiner

    laboratoire structure activité des biomolécules normales et pathologiques, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  7. Juan Carlos Rengifo-Gonzalez

    SABNP, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  8. Hélène Henrie

    SYNSIGHT, Evry, France
    Competing interests
    Hélène Henrie, Synsight has acquired a license for the MT bench" patent (WO2016012451A1) concerning the industrial applications. Hélène Henrie is affiliated with SYNSIGHT. The author has no financial interests to declare.".
  9. Marie-Jeanne Clement

    SABNP, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  10. Vandana Joshi

    laboratoire structure activité des biomolécules normales et pathologiques, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  11. Ahmed Bouhss

    Structure-Activité des Biomolécules Normales et Pathologiques (SABNP), Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6492-1429
  12. Liya Wang

    Structure-Activité des Biomolécules Normales et Pathologiques (SABNP), Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7119-8665
  13. Cyril Bauvais

    SYNSIGHT, Evry, France
    Competing interests
    Cyril Bauvais, Synsight has acquired a license for the MT bench" patent (WO2016012451A1) concerning the industrial applications. Cyril Bauvais is affiliated with SYNSIGHT. The author has no financial interests to declare.".
  14. David Pastré

    SABNP, Université Paris-Saclay, INSERM U1204, Evry, France
    For correspondence
    david.pastre@univ-evry.fr
    Competing interests
    No competing interests declared.

Funding

HORIZON EUROPE Marie Sklodowska-Curie Actions (895024)

  • Krystel El Hage

Genopole (SATURNE 2020)

  • David Pastré

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. José D Faraldo-Gómez, National Institutes of Health, United States

Version history

  1. Preprint posted: April 10, 2022 (view preprint)
  2. Received: May 18, 2022
  3. Accepted: January 17, 2023
  4. Accepted Manuscript published: January 18, 2023 (version 1)
  5. Version of Record published: February 13, 2023 (version 2)

Copyright

© 2023, El Hage et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,753
    views
  • 407
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Krystel El Hage
  2. Nicolas Babault
  3. Olek Maciejak
  4. Bénédicte Desforges
  5. Pierrick Craveur
  6. Emilie Steiner
  7. Juan Carlos Rengifo-Gonzalez
  8. Hélène Henrie
  9. Marie-Jeanne Clement
  10. Vandana Joshi
  11. Ahmed Bouhss
  12. Liya Wang
  13. Cyril Bauvais
  14. David Pastré
(2023)
Targeting RNA:protein interactions with an integrative approach leads to the identification of potent YBX1 inhibitors
eLife 12:e80387.
https://doi.org/10.7554/eLife.80387

Share this article

https://doi.org/10.7554/eLife.80387

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Amy H Andreotti, Volker Dötsch
    Editorial

    The articles in this special issue highlight how modern cellular, biochemical, biophysical and computational techniques are allowing deeper and more detailed studies of allosteric kinase regulation.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Carlo Giannangelo, Matthew P Challis ... Darren J Creek
    Research Article

    New antimalarial drug candidates that act via novel mechanisms are urgently needed to combat malaria drug resistance. Here, we describe the multi-omic chemical validation of Plasmodium M1 alanyl metalloaminopeptidase as an attractive drug target using the selective inhibitor, MIPS2673. MIPS2673 demonstrated potent inhibition of recombinant Plasmodium falciparum (PfA-M1) and Plasmodium vivax (PvA-M1) M1 metalloaminopeptidases, with selectivity over other Plasmodium and human aminopeptidases, and displayed excellent in vitro antimalarial activity with no significant host cytotoxicity. Orthogonal label-free chemoproteomic methods based on thermal stability and limited proteolysis of whole parasite lysates revealed that MIPS2673 solely targets PfA-M1 in parasites, with limited proteolysis also enabling estimation of the binding site on PfA-M1 to within ~5 Å of that determined by X-ray crystallography. Finally, functional investigation by untargeted metabolomics demonstrated that MIPS2673 inhibits the key role of PfA-M1 in haemoglobin digestion. Combined, our unbiased multi-omic target deconvolution methods confirmed the on-target activity of MIPS2673, and validated selective inhibition of M1 alanyl metalloaminopeptidase as a promising antimalarial strategy.